13 February 2022
: Case report 
Pulmonary Function and Chest Computed Tomography (CT) Scan Findings After Antifibrotic Treatment for COVID-19-Related Pulmonary Fibrosis
Unusual setting of medical care
Jan Michael Jesse Lomanta1ABCDEF*, Milraam L. Quinto12BCDEF, Sheen C. Urquiza3CD, Joel M. Santiaguel14ADEFDOI: 10.12659/AJCR.934830
Am J Case Rep 2022; 23:e934830
Table 1. Summary of 6-Minute Walk Test, Pulmonary Function Test, and Chest CT Score Results.
| Baseline | 1 month after Nintedanib treatment | 6 months after Nintedanib treatment | |
|---|---|---|---|
| 6-minute walk distance | 297 meters | 434 meters | 457meters |
| Oxygen supplementation | 2 lpm | 2 lpm | None |
| Borg dyspnea scale | 7 (very severe) | 4 (somewhat severe) | 1 (very slight) |
| FEV1/FVC | 0.90 | 0.80 | 0.80 |
| FEV1 | 54% | 64% | 81% |
| FVC | 0.49 | 0.62 | 0.75 |
| TLC | 52% | 64% | 81% |
| DLCO | 28% predicted (severely reduced) | 36% predicted (moderately reduced) | 59% predicted (moderately reduced) |
| Chest CT scoring | 18 | 16 | 15 |
| * Predicted distance=533 meters; ** severity score: 7 or less=mild, 8–17=moderate, 18 or more=severe. FEV1 – forced expiratory volume at 1 second; FVC – forced vital capacity; TLC – total lung capacity; DLCO – diffusing capacity of the lung for carbon monoxide; LPM – liters per minute. | |||